Dan [Analyst]'s questions to Kura Oncology Inc (KURA) leadership • Q1 2025
Question
Dan, on behalf of Li, asked for expectations on the upcoming ziftomenib combination data with venetoclax/azacitidine, what metrics would be considered competitive, and for an update on the frontline trial initiation timeline.
Answer
Executive Mollie Leoni explained that safety is the primary focus for the combination data, but they will also assess time on treatment and overall patient responses. CEO Troy Wilson confirmed that the frontline study remains on track to begin in the second half of 2025.